Commit Biologics has announced the appointment of Janine Schuurman to its Board of Directors. Janine is a widely recognised ...

AbbVie and Genmab’s would-be blockbuster epcoritamab has been recommended for conditional approval in the EU as a treatment for diffuse large B-cell lymphoma (DLBCL), an aggressive form of non ...

Jurrien Timmer, Director of Global Macro at Fidelity Management & Research Company shared his outlook for 2025.

We recently published a list of 12 High Growth International Stocks to Invest in Now. In this article, we are going to take a ...

AbbVie will pay Danish antibody specialist Genmab $750 million upfront for rights to a series of drugs headed by epcoritamab, a bispecific antibody in development for non-Hodgkin’s lymphoma.

Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies. In addition, the company ...

MP0533 also binds CD3, which is expressed on cytotoxic T-cells and is the principle mechanism of action of approved T-cell engagers like blinatumomab, tarlatamab, epcoritamab, and others.

Epcoritamab-bysp showed a 69% objective response rate and 62% complete response rate in older patients with large B-cell lymphoma who were ineligible for anthracycline-based therapy. Haydar ...

An international team of doctors led by Joshua Brody, MD, Director of the Lymphoma Immunotherapy Program at The Tisch Cancer Institute at Mount Sinai, has made a major breakthrough in treating a ...

Panelists discuss how comparative data from matching-adjusted indirect comparison (MAIC) analyses guide treatment decisions between bispecific therapies and the insights from MAIC results comparing ...

Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and ...